Endocrine therapies, ranging from selective estrogen receptor modulators and downregulators (SERMs, SERDs) to aromatase inhibitors, are the backbone of our current standard of care for the clinical management of ER+ breast cancers [2]. This evidence concerns the gene CYP19A1 and breast cancer.